Daniel P. O'Day's most recent trade in Gilead Sciences, Inc. was a trade of 115,640 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2026 | 115,640 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 150.00 per share. | 05 Feb 2026 | 115,640 | 613,912 (0%) | 0% | 150 | 17,346,000 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 05 Feb 2026 | 115,640 | 729,552 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 131,675 | 688,373 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.28 per share. | 03 Feb 2026 | 74,461 | 613,912 (0%) | 0% | 143.3 | 10,668,772 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 139.54 per share. | 28 Jan 2026 | 5,032 | 561,666 (0%) | 0% | 139.5 | 702,186 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 140.24 per share. | 28 Jan 2026 | 4,968 | 556,698 (0%) | 0% | 140.2 | 696,725 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 23 Jan 2026 | 115,640 | 682,338 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2026 | 115,640 | 115,640 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 23 Jan 2026 | 115,640 | 566,698 (0%) | 0% | 135 | 15,611,400 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 124.83 per share. | 29 Dec 2025 | 10,000 | 566,698 (0%) | 0% | 124.8 | 1,248,272 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 88,070 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 581,629 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.34 per share. | 10 Dec 2025 | 4,931 | 576,698 (0%) | 0% | 121.3 | 598,328 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 126.84 per share. | 28 Nov 2025 | 6,788 | 571,203 (0%) | 0% | 126.8 | 861,016 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 125.91 per share. | 28 Nov 2025 | 3,212 | 577,991 (0%) | 0% | 125.9 | 404,428 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 119.54 per share. | 28 Oct 2025 | 7,978 | 583,225 (0%) | 0% | 119.5 | 953,667 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 118.82 per share. | 28 Oct 2025 | 2,022 | 581,203 (0%) | 0% | 118.8 | 240,259 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.47 per share. | 29 Sep 2025 | 8,039 | 593,164 (0%) | 0% | 111.5 | 896,110 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 112.42 per share. | 29 Sep 2025 | 1,961 | 591,203 (0%) | 0% | 112.4 | 220,454 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 606,152 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 98,496 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.25 per share. | 10 Sep 2025 | 4,949 | 601,203 (0%) | 0% | 115.2 | 570,372 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.63 per share. | 28 Aug 2025 | 10,000 | 595,725 (0%) | 0% | 113.6 | 1,136,300 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 114.09 per share. | 28 Jul 2025 | 8,345 | 605,725 (0%) | 0% | 114.1 | 952,077 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.17 per share. | 28 Jul 2025 | 1,655 | 614,070 (0%) | 0% | 113.2 | 187,293 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.40 per share. | 30 Jun 2025 | 9,400 | 616,325 (0%) | 0% | 110.4 | 1,037,796 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.15 per share. | 30 Jun 2025 | 600 | 615,725 (0%) | 0% | 111.1 | 66,688 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 108,923 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 630,693 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 4,968 | 625,725 (0%) | 0% | 110.1 | 546,927 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.11 per share. | 30 May 2025 | 6,416 | 623,852 (0%) | 0% | 110.1 | 706,497 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.96 per share. | 30 May 2025 | 3,584 | 620,268 (0%) | 0% | 111.0 | 397,696 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 169,690 | 169,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,395 | 119,348 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 80,953 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 641,900 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 11,632 | 630,268 (0%) | 0% | 117.2 | 1,363,387 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 164,473 | 726,032 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 108,156 | 617,876 (0%) | 0% | 98.0 | 10,598,206 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,031 | 561,559 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 506,290 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 104,977 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 4,762 | 501,528 (0%) | 0% | 92.3 | 439,723 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 500,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 115,272 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 4,749 | 495,995 (0%) | 0% | 81.4 | 386,759 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 125,567 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 495,142 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 4,693 | 490,449 (0%) | 0% | 65.2 | 306,218 | Common Stock |